PRISMAP’s access platform, www.prismap.eu is used to convey information and collect the community’s input, alongside a private consortium section for data sharing and communication. Our portfolio covers today 28 different radionuclides, that can be used as active ingredients in diagnostics, treatment, or for theranostics, with the recent addition of four radionuclides requested by the emerging PRISMAP community. Our platform allows scientists interested in biomedical research to easily access synthetic information, such as the type of diagnostic, imaging, or treatment modality, that directly depends on the chemical, physical and nuclear properties of a given radionuclide.
For each radionuclide we provide general information, together with the mode of production and general applications of the radionuclides in biomedical research with links to published articles when available. We also give full specifications of the quality grades supplied by PRISMAP allowing to clarify if the radionuclide with its properties, and the range of purity grades accessible are appropriate for a given field of biomedical research, including recent data produced in PRISMAP.
New terminologies and standards have been introduced to account for the novel methods of production made available across the PRISMAP consortium, notably combining isotope mass separation with accelerator (cyclotron) or reactor methods, allowing our radionuclides to be supplied in high molar activities. Sometimes the data are insufficiently known or not available at all. The produced new data can be useful in the assessment of the physical and nuclear parameters, purity grades, or their application in biomedical research. A new information portal has been established on our platform to provide everybody access to the accepted data as well as the newly created knowledge. This enables the synthesis and use in radiopharmaceuticals targeting specific tumour receptors, as can be seen in our ongoing research projects (
https://www.prismap.eu/about/outcomes/(opens in new window)).
PRISMAP can provide access, free of charge, to new radionuclides and new grades of these to researchers across Europe and beyond, either directly in their laboratory, or by accessing one of our biomedical research centres licensed to handle these new radionuclides.
After 3 additional calls in period 2, a total of 32 user projects from 33 research groups and 12 countries have been selected to develop their research projects. The selected projects cover a wide range of disciplines in radiochemistry, radiation physics, radiopharmacy, preclinical and translational biomedical research, and target different types of cancer and experimental approaches, as the first publications and reports at conferences have shown, e.g. comparing the emerging Tb-161 radiolanthanide efficacy with the Lu-177 benchmark used for neuroendocrine and advanced prostate cancer treatments.
Targeted alpha therapy, an efficient mode of treatment exploiting alpha emitters, also benefits from research and data produced in PRISMAP. This is particularly true for radionuclides which present short half-lives and require efficient dispatch, such as new schemes tested with private air carriers allowing reaching PRISMAP nodes located 2000 km apart in a 4-hour door-to-door lead time, as demonstrated for the delivery of Er-165.
The radionuclides offered by PRISMAP are beyond the common clinical practice and require particular attention for the users, as well as for the future clinical practice. PRISMAP has thus established a training programme that has attracted many talented young researchers, as well as reaching out to established researchers across the disciplines where the PRISMAP community is represented.
